Suppliers and packagers for nexium

nexium

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153	NDA	AstraZeneca Pharmaceuticals LP	0186-5020-31	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5020-31)	2001-03-19
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153	NDA	AstraZeneca Pharmaceuticals LP	0186-5020-54	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5020-54)	2001-03-19
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153	NDA	AstraZeneca Pharmaceuticals LP	0186-5040-31	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5040-31)	2001-03-19
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153	NDA	AstraZeneca Pharmaceuticals LP	0186-5040-54	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5040-54)	2001-03-19
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957	NDA	AstraZeneca Pharmaceuticals LP	0186-4020-01	30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4020-01)	2007-03-19
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957	NDA	AstraZeneca Pharmaceuticals LP	0186-4025-01	30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4025-01)	2012-06-01
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957	NDA	AstraZeneca Pharmaceuticals LP	0186-4040-01	30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4040-01)	2007-03-19

NEXIUM (Esomeprazole Magnesium) Supply Chain and Key Patent Landscape

Last updated: February 19, 2026

This report analyzes the supply chain and patent landscape for NEXIUM (esomeprazole magnesium), a proton pump inhibitor (PPI) used to treat conditions associated with excessive stomach acid production. Key manufacturers and API suppliers are identified, alongside an overview of relevant patent expirations and litigation impacting market exclusivity.

What is NEXIUM and What is its Market Position?

NEXIUM is the brand name for esomeprazole magnesium, a selective and irreversible inhibitor of the gastric H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells. It reduces the production of stomach acid. The primary indications for NEXIUM include treatment of erosive esophagitis, healing of heartburn associated with gastroesophageal reflux disease (GERD), and maintenance of healing of erosive esophagitis. It is also used for the long-term treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

The global market for PPIs is substantial, driven by the high prevalence of acid-related gastrointestinal disorders. NEXIUM, as a second-generation PPI, has historically held a significant market share due to its efficacy and established safety profile. However, the market has seen increased competition with the advent of generic esomeprazole.

Therapeutic Class	Primary Use Cases
Proton Pump Inhibitor (PPI)	Erosive esophagitis healing and maintenance, GERD heartburn, pathological hypersecretory conditions

The total prescription market for esomeprazole has been influenced by factors such as patent expirations, generic competition, and evolving treatment guidelines. Data from IQVIA (formerly IMS Health) indicates that the overall esomeprazole market, encompassing both brand and generic, has undergone significant price erosion post-exclusivity.

Who are the Key Manufacturers and Suppliers of NEXIUM?

The primary manufacturer and marketer of brand-name NEXIUM has been AstraZeneca. However, the landscape has shifted with the introduction of generic versions.

Brand-Name Manufacturer

• AstraZeneca: The originator company for NEXIUM. They manage the production, marketing, and distribution of the branded product in various global markets.

Generic Manufacturers

Following the expiration of key patents, numerous generic pharmaceutical companies have entered the market, producing their own versions of esomeprazole magnesium. This includes companies that formulate finished dosage forms and those that supply the active pharmaceutical ingredient (API).

Key Global Generic Manufacturers (Indicative List):

• Teva Pharmaceuticals: A leading global generic drug manufacturer with a significant presence in esomeprazole production.
• Mylan N.V. (now Viatris): Another major player in the generic pharmaceutical space, offering esomeprazole magnesium products.
• Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company that manufactures and supplies generic APIs and finished dosage forms.
• Sun Pharmaceutical Industries Ltd.: A global specialty pharmaceutical company with a broad portfolio of generics, including esomeprazole.
• Aurobindo Pharma Ltd.: An Indian vertically integrated pharmaceutical company involved in the manufacturing of APIs and finished formulations.
• Lupin Limited: An Indian multinational pharmaceutical company producing a range of generics.

These companies may source their APIs from specialized chemical manufacturers or produce them in-house.

Active Pharmaceutical Ingredient (API) Suppliers

The synthesis of esomeprazole magnesium involves complex chemical processes. API suppliers are critical to the overall supply chain, ensuring the availability of the core drug substance.

Examples of API Suppliers (Note: This is not exhaustive and can change due to market dynamics):

• AstraZeneca: May continue to supply API for its branded product or to select partners.
• Major Indian API Manufacturers: Many Indian pharmaceutical companies are significant global suppliers of APIs for a wide range of drugs, including esomeprazole. This includes companies like:
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Divi's Laboratories
  • Lupin Limited
  • Aurobindo Pharma Ltd.
• Chinese API Manufacturers: Several Chinese chemical and pharmaceutical companies are also active in the global API market for esomeprazole. Specific company names are subject to change based on regulatory approvals and market contracts.

The selection of API suppliers by generic manufacturers is often based on cost, quality, regulatory compliance (e.g., FDA, EMA GMP standards), and supply chain reliability.

What is the Patent Landscape for NEXIUM?

The patent landscape for NEXIUM is complex, involving patents on the active compound, methods of synthesis, formulations, and specific uses. The expiration of these patents has been the primary driver for generic entry.

Key Patents and Expiration Dates

The original patent for omeprazole, the racemic mixture from which esomeprazole is derived, has long expired. Esomeprazole is the S-isomer of omeprazole. The patent protection for esomeprazole itself was critical for AstraZeneca's market exclusivity.

• US Patent No. 5,489,585: This patent, related to optically pure omeprazole enantiomers, was a key patent protecting esomeprazole. It was originally set to expire in 2011 but received patent term extensions. Generic companies challenged this patent and its extensions.
• Other Formulation and Method Patents: AstraZeneca also held patents related to specific pharmaceutical formulations (e.g., delayed-release tablets), manufacturing processes, and new indications or polymorphic forms. These patents had varying expiration dates.

General Patent Expiration Timeline (US Focus):

• Early 2010s: Major patents, including those for the active compound and key formulations, began to expire in the United States.
• 2011: Initial expiration of primary patent protection for esomeprazole in the U.S.
• Subsequent Years: Expirations of secondary patents related to formulations and manufacturing processes.

The exact expiration dates and the outcome of patent litigation vary by country due to differences in patent law, patent term extension provisions, and legal challenges.

Patent Litigation and Generic Entry

The entry of generic esomeprazole was preceded by extensive patent litigation. Generic manufacturers sought to invalidate AstraZeneca's patents or demonstrate that their products did not infringe.

• ANDA Filings: Generic companies file Abbreviated New Drug Applications (ANDAs) with regulatory agencies like the U.S. Food and Drug Administration (FDA). These applications demonstrate that the generic product is bioequivalent to the branded product and that the relevant patents are either expired, invalid, or will not be infringed.
• Paragraph IV Certifications: In ANDAs, generic companies often assert that the patents listed in the FDA's Orange Book are invalid, unenforceable, or will not be infringed. This triggers a 30-month stay of FDA approval in many cases if the patent holder sues for infringement.
• Key Litigation Outcomes: Numerous lawsuits were filed by AstraZeneca against generic companies for alleged patent infringement. The outcomes of these cases often determined the timing of generic market entry. For instance, legal challenges to AstraZeneca's patents by Teva and other generic manufacturers were pivotal in paving the way for generic esomeprazole.

Impact of Patent Expiration:

Upon patent expiration and successful navigation of litigation, the market for NEXIUM transitioned from a monopolistic branded market to a highly competitive generic market. This resulted in:

• Price Erosion: Significant reduction in the average selling price of esomeprazole.
• Increased Accessibility: Wider availability of esomeprazole at lower costs.
• Shift in Market Share: A substantial decline in market share for branded NEXIUM, with generic versions capturing the majority of prescriptions.

How is NEXIUM Manufactured?

The manufacturing of esomeprazole magnesium involves a multi-step chemical synthesis process to produce the API, followed by formulation into finished dosage forms.

API Synthesis

Esomeprazole is the (S)-enantiomer of omeprazole. The synthesis typically starts with precursor chemicals and involves stereoselective synthesis or resolution of racemic omeprazole.

1. Starting Materials: Key starting materials include substituted pyridines and benzimidazoles.
2. Key Reactions:
   • Formation of the benzimidazole ring.
   • Coupling of the pyridine and benzimidazole moieties.
   • Oxidation to form the sulfoxide, which is the chiral center.
3. Chiral Separation/Synthesis:
   • Chiral Resolution: Racemic omeprazole can be synthesized first, followed by separation of the (S)- and (R)-enantiomers using chiral chromatography or chiral resolving agents.
   • Asymmetric Synthesis: More advanced methods involve directly synthesizing the (S)-enantiomer using chiral catalysts or auxiliaries. This approach is often more efficient and cost-effective.
4. Salt Formation: The final API is typically isolated as a magnesium salt (esomeprazole magnesium) for stability and formulation purposes. This involves reacting the free base esomeprazole with a magnesium source under controlled conditions.
5. Purification and Crystallization: The API undergoes rigorous purification steps, including crystallization, to meet strict pharmaceutical purity standards.

Regulatory Requirements: API manufacturing must comply with Good Manufacturing Practices (GMPs). Facilities are inspected by regulatory bodies like the FDA and EMA.

Finished Dosage Form Manufacturing

The API (esomeprazole magnesium) is then formulated into tablets, capsules, or oral suspensions. NEXIUM is most commonly known for its delayed-release formulations.

1. Excipient Blending: The esomeprazole magnesium API is blended with various pharmaceutical excipients. These include:
   • Fillers/Diluents: Microcrystalline cellulose, lactose.
   • Binders: Hydroxypropyl cellulose.
   • Disintegrants: Crospovidone.
   • Lubricants: Magnesium stearate.
   • Glidants: Colloidal silicon dioxide.
2. Granulation (if applicable): Wet or dry granulation may be used to improve powder flow and compressibility.
3. Tablet Compression or Capsule Filling: The blend is compressed into tablets or filled into capsules.
4. Coating: This is a critical step for delayed-release formulations. The tablets or granules are coated with polymers that are stable at gastric pH but dissolve in the higher pH of the small intestine. Common coating materials include methacrylic acid copolymers.
5. Packaging: Finished products are packaged into bottles or blister packs, adhering to pharmaceutical packaging standards to ensure stability and prevent degradation.

Quality Control: Throughout the manufacturing process, extensive quality control testing is performed on raw materials, in-process samples, and finished products to ensure identity, strength, quality, and purity.

What are the Regulatory Considerations?

The manufacturing and marketing of esomeprazole magnesium are subject to stringent regulations by health authorities worldwide.

Drug Approval Process

• ANDA Requirements (Generics): Generic manufacturers must demonstrate bioequivalence to the reference listed drug (NEXIUM) through in vivo studies and show that their manufacturing process ensures consistent quality.
• New Drug Application (NDA) (Originator): AstraZeneca submitted an NDA for NEXIUM, which included comprehensive data on safety, efficacy, manufacturing, and quality.

Good Manufacturing Practices (GMP)

All manufacturing facilities involved in producing esomeprazole magnesium API and finished drug products must adhere to current GMP regulations (e.g., 21 CFR Part 210/211 in the US, EudraLex Volume 4 in the EU). These regulations cover:

• Facility design and maintenance.
• Equipment qualification and calibration.
• Personnel training and hygiene.
• Raw material control.
• Process validation.
• Quality control and assurance.
• Record keeping.

Pharmacopeial Standards

Esomeprazole magnesium must meet the specifications outlined in official pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define tests for identity, assay, impurities, dissolution, and other critical quality attributes.

Supply Chain Security and Traceability

Regulations increasingly require robust measures for drug supply chain security and traceability to prevent counterfeiting and diversion. This includes serialization and track-and-trace requirements.

Key Takeaways

• NEXIUM (esomeprazole magnesium) has transitioned from a branded, high-revenue product to a competitive generic market following patent expirations.
• AstraZeneca is the originator and primary manufacturer of branded NEXIUM.
• The generic market for esomeprazole is populated by numerous global manufacturers, including Teva, Mylan (Viatris), Dr. Reddy's, and Sun Pharma.
• API supply is critical, with significant contributions from both Indian and Chinese manufacturers, alongside in-house production by major generic firms.
• Key patent protection for esomeprazole, particularly US Patent No. 5,489,585, expired in the early 2010s, triggering extensive litigation and paving the way for generic entry.
• Manufacturing involves complex stereoselective chemical synthesis for the API and sophisticated delayed-release coating technologies for the finished dosage form.
• All manufacturing and supply chain activities are governed by stringent global regulatory requirements, including GMP standards and pharmacopeial specifications.

FAQs

What are the main impurities found in esomeprazole magnesium?

Impurities can arise from starting materials, reagents, by-products of synthesis, or degradation. Common impurities for esomeprazole include unreacted starting materials, isomers (e.g., the R-enantiomer), oxidation products, and residual solvents. Regulatory agencies set strict limits for these impurities based on pharmacopeial monographs and ICH guidelines.

How does the bioequivalence of generic esomeprazole compare to brand-name NEXIUM?

Generic esomeprazole products must demonstrate bioequivalence to the reference listed drug (NEXIUM) through pharmacokinetic studies. This means that the rate and extent of drug absorption into the bloodstream are comparable, ensuring that the generic product provides the same therapeutic effect.

What is the typical shelf life for esomeprazole magnesium products?

The shelf life for esomeprazole magnesium products, including NEXIUM and its generic equivalents, is typically determined by stability studies and is generally between 24 to 36 months when stored under recommended conditions. The specific expiration date is printed on the product packaging.

Are there any specific geographical regions that dominate API production for esomeprazole?

Historically, India and China have emerged as dominant global suppliers for Active Pharmaceutical Ingredients (APIs), including esomeprazole, due to their robust chemical manufacturing capabilities, cost efficiencies, and large manufacturing capacities.

What are the challenges in manufacturing delayed-release esomeprazole formulations?

Manufacturing delayed-release formulations presents several challenges, including ensuring the consistent application and integrity of the enteric coating, which must prevent drug release in the stomach but allow for dissolution in the intestine. Achieving uniform particle size distribution of the API and excipients, proper granulation, and precise compression are also critical for effective tablet formation and consistent dissolution profiles.